HUTCHMED (China) Valuation

Is H7T1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of H7T1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: H7T1 (€18.8) is trading below our estimate of fair value (€54.97)

Significantly Below Fair Value: H7T1 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for H7T1?

Other financial metrics that can be useful for relative valuation.

H7T1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.4x
Enterprise Value/EBITDA-24.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does H7T1's PS Ratio compare to its peers?

The above table shows the PS ratio for H7T1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
DMP Dermapharm Holding
1.5x3.8%€1.7b
PSG PharmaSGP Holding
2.8x7.0%€304.6m
BAYN Bayer
0.5x1.4%€25.1b
MRK Merck KGaA
3.2x4.3%€66.2b
H7T1 HUTCHMED (China)
5.6x18.0%€2.6b

Price-To-Sales vs Peers: H7T1 is expensive based on its Price-To-Sales Ratio (5.6x) compared to the peer average (2x).


Price to Earnings Ratio vs Industry

How does H7T1's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.6%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.6%
n/an/an/a
No more companies

Price-To-Sales vs Industry: H7T1 is expensive based on its Price-To-Sales Ratio (5.6x) compared to the European Pharmaceuticals industry average (3.4x).


Price to Sales Ratio vs Fair Ratio

What is H7T1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

H7T1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.6x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: H7T1 is expensive based on its Price-To-Sales Ratio (5.6x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies